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Autosomal Dominant Polycystic Kidney Disease (ADPKD) is a major cause of end-stage renal 
disease in man. The central role of cyclic adenosine monophosphate (cAMP) in ADPKD 
pathogenesis has been confirmed by numerous studies including positive clinical trial data. In 
this study, we investigated the potential role of another major regulator of renal cAMP, 
prostaglandin E2 (PGE2), in modifying disease progression in ADPKD models using selective 
receptor modulators to all four PGE2 receptor subtypes (EP1-4). In 3D-culture model systems 
utilising dog (MDCK) and human-derived (UCL93, OX161-C1) kidney cell lines, PGE2 
strikingly promoted cystogenesis and inhibited tubulogenesis by stimulating proliferation and 
reducing apoptosis. The effect of PGE2 on tubulogenesis and cystogenesis in 3D-culture was 
mimicked or abolished by selective EP2 and EP4 agonists or antagonists but not those specific 
to EP1 or EP3. In a Pkd1 mouse model (Pkd1nl/nl), renal PGE2 and COX-2 expression were 
increased by ~2-fold at the peak of disease (week 4). However, Pkd1nl/nl mice treated with 
selective EP2 (PF-04418948) or EP4 (ONO-AE3-208) antagonists from birth for 3 weeks had 
more severe cystic disease and fibrosis associated with increased cell proliferation and 
macrophage infiltration. A similar effect was observed for the EP4 antagonist ONO-AE3-208 
in a second Pkd1 model (Pax8rtTA-TetO-Cre-Pkd1f/f). In conclusion, despite the positive effects 
of slowing cyst growth in vitro, the more complex effects of inhibiting EP2 or EP4 in vivo 
resulted in a worse outcome, possibly related to unexpected pro-inflammatory effects. 
 







ADPKD is the major genetic cause of kidney failure in man with currently limited treatment 
options. Our study sought to investigate whether selective receptor blockade of PGE2 action 
via the EP2 and EP4 receptors which signal mainly via cAMP, could inhibit cyst formation in 
experimental disease models. Despite positive effects in cyst assays, an unexpected increase in 
the cyst burden was observed in two Pkd1 mouse models after in vivo dosing, associated with 
an increase in inflammation. Our results do not support the use of EP2 or EP4 antagonists as 






Autosomal dominant polycystic kidney disease (ADPKD) is the most common kidney genetic 
disorder, accounting for 7–10% of patients with end-stage renal disease, and is caused by 
mutations in two genes, PKD1 (~85%) or PKD2 (~15%) 1. It is characterized by the formation 
of fluid-filled cysts which arise from tubular epithelial cells that exhibit a hyperproliferative 
and pro-apoptotic phenotype 2, 3. Recently, the vasopressin V2 receptor (VPV2R) antagonist, 
tolvaptan, has been approved for the treatment for ADPKD patients with evidence of rapid 
disease progression 4, 5. However, the use of tolvaptan is associated with poorly tolerated side-
effects and a rare but unpredictable incidence of liver toxicity 4. Hence, the discovery of safer 
and more effective alternative drugs to slow disease progression in ADPKD is of major clinical 
interest.  
Prostaglandin E2 (PGE2) is a lipid mediator synthesized from arachidonic acid through several 
enzymatic steps including cyclooxygenases (COX-1 and COX-2) and Prostaglandin E synthase 
6. Several studies suggest that COX-2 is the major cyclooxygenase responsible for PGE2 
production 7, 8. PGE2 binds to four different G-protein coupled receptors (GPCR), EP1-4, which 
are differentially expressed in different tissues and which signal through different G-proteins 
thus resulting in complex outputs 9. In particular, EP2 and EP4 are known to couple to Gs 
which stimulates cyclic adenosine monophosphate (cAMP) formation by activating adenylyl 
cyclase 10. Cyclic AMP is a central player in cyst formation and expansion 11-14. Several GPCR 
ligands (VPV2R, Endothelin B and somatostatin receptors) have been shown to modify disease 
severity in ADPKD models though modulating renal cAMP concentrations 15-18.  
PGE2 has been isolated in cyst fluid 
19 and its urinary concentration found to be increased in 
patients with reduced kidney function 20. In vitro, the effect of PGE2 on stimulating cyst 
formation has been shown on IMCD-3 and human epithelial cells 21, 22. These early 
observations suggested that PGE2 could be a major modifier of cyst growth. However the study 
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of PGE2 signalling has been hampered by the lack of potent and selective receptor modulators 
(agonists and antagonists). Conversely, the more recent availability of these compounds has 
led to a resurgence of preclinical and clinical investigation of different EP subtypes as selective 
targets to treat a variety of orphan diseases 23. 
In this paper, we report the effects of modifying PGE2 signalling on cyst growth by utilising 
new potent and selective receptor modulators to all four EP receptors (EP1-4) in cellular and 
animal models of ADPKD. Our results suggest a striking effect of EP2 and EP4 agonists in 
inhibiting tubulogenesis and promoting cyst formation and expansion in vitro. However the 
administration of EP2 and EP4 antagonists to a neonatal model of ADPKD, the hypomophic 
Pkd1 mouse (Pkd1nl/nl) and a post-natal Cre-inducible Pkd1 model (Pax8rtTA-TetO-Cre-Pkd1f/f) 
led surprisingly to more severe cystic disease. These results suggest a more complex effect of 
EP2 and EP4 antagonists in vivo resulting in a worse outcome in this model, possibly related 
to unexpected pro-inflammatory effects. 
 
RESULTS  
EP2 or EP4 receptor activation inhibit tubulogenesis and promote cystogenesis 
To study the effect of PGE2 on spontaneous tubulogenesis, the normal human renal epithelial 
cell line UCL93 was grown in a Type I collagen matrix. After 20 days, prominent tubule 
structures had formed with evidence of branching (Figure 1A). The addition of different 
concentrations of PGE2 (1-100 nM) after 6 days of culture significantly increased the 
percentage of cystic structures with a 2-fold increase at 10 nM PGE2 (Figure 1B). All four EP 
receptor subtypes are expressed in this line although EP2 and EP4 were more highly expressed 
than EP1 and EP3 (data not shown). Importantly, the effect of PGE2 was mimicked by an EP2 
selective agonist (ONO-AE1-259-01) or an EP4 selective agonist (ONO-AE1-329) suggesting 
that stimulation of either receptor can initiate cyst formation (Figure 1C and D). Stimulation of 
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UCL93 with PGE2, EP2 or EP4 selective agonists stimulated cAMP formation (Figure 1E and 
F) suggesting that cyst formation is cAMP-mediated and involves EP2 and EP4. 
 
PGE2 stimulates cyst growth in MDCK and OX161-C1 cell lines 
The potential effect of PGE2 and its receptors on cyst growth was next studied in 3D-cyst assays 
using the established Madin-Darby canine kidney cell II (MDCK II) and in a human PKD1 
cystic epithelial cell line, OX161-C1 (Figure 2A). The latter expresses all four EP subtypes in 
a similar pattern to UCL93 (data not shown). The addition of PGE2 significantly enhanced cyst 
growth in both cell lines over time in a dose-dependent manner with OX161-C1 cells being 
more sensitive to the effect of PGE2 than MDCK II cells (Figure 2B and C). Since MDCK II 
cysts responded in a clearer dosage-dependent manner than OX161-C1, we investigated the 
effects of PGE2 on proliferation (Ki-67) or apoptotic (cleaved caspase-3) rates in MDCK II 
cysts. PGE2 had a dual effect on MDCK II cysts by increasing cell proliferation and inhibiting 
apoptosis in a dose-dependent manner (Figure 2D-G). We did not measure apoptosis at earlier 
time points and it is possible that luminal apoptotic cells could have been removed. These 
changes were significantly correlated to changes in the average cyst area measured in the same 
wells (Supplementary figure S1A, B). As expected, PGE2 stimulated cAMP accumulation in 
both cell lines (Supplementary figure S1C, D). 
 
EP2 and EP4 agonists mimic PGE2-induced cyst growth 
A differential array of EP gene expression revealed fold-changes of 1.55 (EP1), 5.05 (EP2), -
1.19 (EP3) and 1.89 (EP4) between PKD1 cystic and normal cells although only EP2 was 
significantly increased 24. We confirmed that OX161-C1 expresses all four EP receptor 
subtypes and MDCK II expresses EP2 and EP4 mRNA by PCR (data not shown). We next 
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tested the effects of selective agonists to EP1-4 in both cell lines grown in 3D-culture for up to 
20 days. The EP1 agonist ONO-DI-004 and the EP3 agonist ONO-AE-248 did not significantly 
increase cyst area of either MDCK II or OX161-C1 after 14 days incubation although a 
decrease was noted at the highest concentration of ONO-AE-248 in OX161-C1 (data not 
shown). By contrast, cyst growth in both lines was significantly enhanced by either EP2 (ONO-
AE1-259-01) or EP4 (ONO-AE1-329) agonists in a dose-dependent manner (Figure 3A-D). 
Similar to PGE2, the EP2 and EP4 agonists also enhanced cAMP formation in OX161-C1 and 
MDCK II (Figure 3E and F) and stimulated MDCKII cyst growth by increasing cell 
proliferation and decreasing cell apoptosis (Supplementary Figure S2). These results strongly 
suggested that PGE2 stimulates cyst growth in vitro by activating EP2 and EP4. 
 
EP2 and EP4 antagonists abolish PGE2-induced cyst growth 
To confirm that PGE2-induced cyst growth is mediated by EP2 and EP4, we tested the effect 
of selective EP2 and EP4 antagonists on PGE2-induced cyst growth in both cell lines.  As 
shown in Figure 4, the EP2 antagonist ONO-AE8-111 or the EP4 antagonist ONO-AE8-11 
both decreased the effect of PGE2 on cyst growth. Similar effects were observed with the EP2 
antagonist PF-04418948 and a different EP4 antagonist CJ-42794 (Data not shown). Taken 
together, these results confirm that PGE2 induces cyst growth via EP2 and EP4 and that 
blockade of either receptor is sufficient to inhibit the effect of PGE2. 
 
The PGE2 pathway is up-regulated in an early-onset Pkd1 mouse model 
To study the regulation of the PGE2 pathway in an in vivo ADPKD model, we utilised the early 
onset hypomorphic Pkd1-neolox (Pkd1nl/nl) mouse model 25. In this model, Pkd1nl/nl kidneys 
were already cystic and larger at birth compared to Pkd1wt/wt at each time point (Supplementary 
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Figure S3A–E). Typically, peak kidney growth and cyst expansion occurred around week 3 
followed by a gradual decrease up to week 10 (Figure 5A and B, Supplementary Figure S3F). 
Cysts developed from multiple nephron segments (distal and proximal tubules, collecting ducts 
and loop of Henle) during this growth phase (data not shown). At 3 weeks, Pkd1nl/nl kidneys 
were characterised by an increase in both proliferative (Ki-67 positive) and apoptotic (TUNEL 
positive) cells (Supplementary Figure S4), an accumulation of F4/80-positive cells and fibrotic 
tissue especially around cysts (Supplementary figure S5). Renal cAMP concentrations 
increased significantly from week 2 to 3 in Pkd1nl/nl kidneys but then decreased sharply after 
week 4, changing in parallel to fractional total kidney weights (Figure 5A and C).  
We next analysed different components of the PGE2 system in this model. Levels of Ptgs2 
mRNA (encoding for COX-2) were increased in Pkd1nl/nl kidneys from weeks 2 to 6 followed 
by a decline up to week 10 (Figure 5D). In 4 week old animals, PGE2 concentrations in whole 
kidney lysates was increased by at least two-fold: 537 pg/mg protein (Pkd1wtwt) vs 1174 pg/mg 
protein (Pkd1nl/nl) (Figure 5E). The expression profile of the different PGE2 receptors showed 
distinct expression patterns over time (Supplementary Figure S6). Ptger1 and Ptger4 mRNA 
were significantly up-regulated in Pkd1nl/nl kidney from week 4 to 10 with a peak at week 6 
while Ptger2 was significantly up-regulated at week 2 and also from week 6 to 10. Ptger3 
expression was lower in Pkd1nl/nl kidneys between weeks 2 to 6 though this did not reach 
significance. In 2 week-old Pkd1wt/wt kidneys, EP4 was strongly expressed by distal tubules and 
the loops of Henle, co-localising with calbindin and Tamm-Horsfall protein respectively in 
serial sections (Supplementary Figure S7A). In 2week-old Pkd1nl/nl kidneys, EP4 was detected 
in small cysts and dilated tubules but was not expressed in larger cysts (Supplementary Figure 




EP2 and EP4 receptor blockade increases disease severity in vivo in an early-onset Pkd1 
mouse model 
Since cyst formation occurred in utero and was obvious in newborn (PN1) Pkd1nl/nl mice 
(Supplementary Figure S3), we decided to commence drug treatment shortly after birth. To 
achieve this, compounds were initially administered through the drinking water (PN1-7) of 
lactating mothers and after the first week of life, by daily IP injection (PN7–20) to the pups. 
Four treatment groups each received either DMSO (vehicle), the EP2 antagonist PF-04418948, 
the EP4 antagonist ONO-AE3-208 or both compounds in combination (Figure 6A). Animals 
from all four groups grew normally and tolerated the compounds with normal increases in body 
weight (data not shown). Unexpectedly, the average kidney weights and kidney-to-body weight 
ratio from PN21 mice treated with either EP2 or EP4 antagonists alone did not decrease but 
were higher (Figure 6B–D) with a significant increase for the EP4 antagonist treated animals. 
Histological analysis of kidney sections showed that the cystic index in both EP2 and EP4 
treated groups were significantly higher than those of vehicle treated animals (Figure 6E and 
F) with a non-significant trend (p=0.056) towards increased fibrosis (Supplementary figure 
S8D). Kidney function was not significantly altered between the groups nor was there a 
significant change in total kidney cAMP content or apoptosis (Supplementary figure 8A-C). 
However, the percentage of Ki-67-positive cells and F4/80-positive cells was significantly 
increased in both EP2 and EP4 groups with a significant correlation between the percentage of 
F4/80-positive cells and kidney-to-body weight ratio (Figure 6G-I). Compared to vehicle 
treated animals, mice treated with EP2 and EP4 antagonists in combination had a less severe 
phenotype than those treated with either compound alone associated with a trend towards 
reduced fibrosis, cell proliferation and macrophage number. Treated animals did not show any 
significant change between AQP1 and AQP2 positive tubules excluding a differential effect on 
segment-specific cysts (Supplementary figure S9). 
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EP4 receptor blockade in vivo increases disease severity in an inducible kidney-specific 
Pkd1 model 
To confirm these findings, we utilised a second Pkd1 mouse model (Pax8rtTA-TetO-Cre-Pkd1f/f) 
26 to induce kidney-specific post-natal Pkd1 deletion (PN13-15) by doxycycline (DOX) IP 
injection which generates a less severe model than Pkd1nl/nl mice. Post-induction, mice were 
treated by daily IP injection for 14d (PN16–29) prior to sacrifice at PN30. The four treatment 
groups received either DMSO (vehicle), the EP2 antagonist PF-04418948, the EP4 antagonist 
ONOAE3-208 or both compounds in combination (Figure 7A).  Average kidney weights and 
kidney-to-body weight ratios treated with the EP4 antagonist were higher than vehicle or EP2 
treated mice with a non-significant increase in the EP4 antagonist treated animals (Figure 7B–
D). Although there was no significant change in cystic index, cyst number in the EP4 treated 
group was higher (p=0.053) than vehicle treated animals (Figure 7E-G) and was associated 
with a significant increase in the percentage of Ki-67-positive cells and F4/80-positive cells 
(Figure 7H-I).  As in the first model (Pkd1nl/nl), the percentage of F4/80-positive cells and 
kidney-to-body weight ratio showed a highly significant correlation (Figure 7J).  
 
EP4 receptor blockade in vivo increases accumulation of M2 macrophages in both Pkd1 
models. 
The observed increase in macrophage number particularly following EP4 receptor blockade 
led us to investigate whether there was a shift in macrophage polarisation between M1 (Nos2 
positive) and M2 (Ym1 or Mrc1 positive) subtypes by immunohistochemistry and 
immunofluorescence labelling. In both models, M2 macrophages (Ym1 or Mrc1) were 
significantly increased in the EP4 group (Figure 8) whereas the percentage of M1 macrophages 




In this study, we present clear evidence that PGE2 promotes cystogenesis in cellular 
models of ADPKD via the EP2 and EP4 receptors. Since EP2 and EP4 are known to couple to 
Gs which stimulates cAMP formation by activating adenylyl cyclase 27, 28, this confirms that 
the pro-cystogenic action of PGE2 is via cAMP formation. Using selective receptor agonists, 
we exclude a major role for EP3, which inhibits cAMP generation via Gi 29 and EP1, which 
activates Gq, leading to intracellular Ca2+ elevation through phospholipase C 30. The effect of 
PGE2 acting via EP2 and EP4 was particularly striking on inhibiting normal tubulogenesis and 
promoting cystogenesis in a non-cystic human cell line (UCL93). The action of EP2 and EP4 
appeared to be independent and non-redundant in both MDCK and OX161-C1. We did not 
observe a change in the pattern of EP receptor expression between normal (UCL93) or PKD1 
cystic cells. Our results differ from previous reports suggesting a more restricted role for EP2 
or EP4 in mediating the action of PGE2 on cyst formation in primary human cystic cells or 
murine IMCD-3 cells respectively 21, 22. These differences could reflect cell type differences in 
EP expression. 
The promising effects observed using EP2 and EP4 antagonists on PGE2-induced cyst 
growth in vitro were however not reproduced in vivo. We chose to study a well-established 
Pkd1 mouse model (Pkd1nl/nl) which has an early-onset phenotype but whose phenotype has 
been shown to respond to several therapeutic drugs 31-34. Both PGE2 concentration and Ptgs2 
expression were increased at the peak of cystic disease (3-4 weeks) in parallel to the increase 
in renal cAMP concentrations. Since cyst formation was already significant at birth, we decided 
to administer EP2 or EP4 antagonists from PN1-21 to cover the peak period of cyst formation. 
Unexpectedly, blockade of either receptor led to an increase in the severity of disease and was 
associated with an increase in cell proliferation and macrophage infiltration. Similar results 
were observed for EP4 blockade in a second Pkd1 model (Pax8rtTA-TetO-Cre-Pkd1f/f) with 
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post-natal disease onset although in this model, the effect of EP2 antagonism was neutral. 
These could represent differences relating to the timing of disease onset in both models ie 
neonatal (hypomorphic) and post-natal (inducible). 
The simplest explanation for our findings is that EP2 and EP4 antagonism led to a pro-
inflammatory phenotype in vivo. Indeed, the role of PGE2 in inflammation is complex as it has 
been reported to exert both pro- and anti-inflammatory responses, depending on the tissue and 
receptor expression 35, 36. The role of EP4 in kidney inflammation has been investigated more 
extensively than EP2. In the Unilateral Ureteral Obstruction (UUO) model which is 
characterized by increases in PGE2, COX-2, EP2 and EP4 mRNA, EP4-null mice developed 
more interstitial fibrosis and macrophage infiltration compared to wild-type UUO mice 37. 
Conversely, treating UUO-wild type mice with an EP4 agonist (ONO-4819) reduced interstitial 
fibrosis and macrophages number 37. A similar effect of a different EP4 agonist (CP-044,519-
02) on fibrosis and macrophage infiltration was noted in the subtotal (5/6) nephrectomy model 
of chronic kidney failure 38. These observations are not restricted to kidney disease models as 
EP4-null mice develop greater airway inflammation than their wild-type controls in three 
models of airway inflammation 39. The anti-inflammatory effect of EP4 on macrophages could 
relate to alternative non-Gs/cAMP pathways such as EP4 receptor-associated protein/β-arrestin 
signalling in these cells 40.  
By contrast, the role of EP2 in kidney disease models has not been studied in detail. 
However, a likely role in the regulation of macrophage maturation has emerged. EP2 
expression is upregulated in activated peritoneal macrophages 41 but EP2-null macrophages or 
macrophages treated with EP2 antagonist exhibit enhanced maturation in vitro; EP2-null mice 
had higher numbers of circulating mature macrophages and in the peritoneal cavity 42. The 
removal of this restraint on systemic macrophage maturation could have contributed to 
increased macrophage recruitment in EP2-treated Pkd1 hypomorphic mice. 
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Several recent papers have highlighted the role that macrophages could play in 
modifying disease severity in other murine models of ADPKD 43, 44. Macrophages have been 
shown to promote cyst growth by both proliferation-dependent and proliferation-independent 
mechanisms45. Typically, alternatively activated (M2-like) macrophages have been associated 
with tubular proliferation whereas pro-inflammatory (M1-like) macrophages can lead to cyst 
expansion through tubular injury 45, 46. Conversely, the cystic epithelium can play a direct role 
in stimulating macrophage infiltration (MCP-1 secretion) or polarisation to M2 phenotypes (L-
lactic acid secretion) 46. Our results add cystic-derived PGE2 to the emerging epithelial-
macrophage axis in ADPKD as both a pro-proliferative and anti-inflammatory mediator. Our 
in vivo results were more complex than anticipated due to the opposing effects of EP2 and EP4 
on epithelial proliferation and macrophage infiltration or activation. Of interest, mice treated 
with EP2 and EP4 antagonists in combination had similar proliferative rates to vehicle-treated 
mice but still had more macrophages and a higher cystic index. These results suggest that the 
direct effects of EP2 and EP4 antagonists in blocking PGE2-stimulated epithelial cell 
proliferation (that we observed in vitro) was unable to counterbalance the negative effect of 
increased macrophage infiltration or activation that led to both proliferation and injury. A 
consistent effect in both models was the increase in F4/80 positive macrophage number 
(especially M2-like) following EP4 receptor blockade. Our data therefore add to the 
accumulating evidence that macrophages play a key role in modifying cystogenesis in ADPKD. 
The complexity of different macrophage subpopulations in healthy and diseased kidney has 
been reported recently by several groups. Of potential relevance to our findings was the 
reaccumulation of a ‘juvenile-like’ resident macrophage population (R2b) in pre-cystic kidneys 
of a cilia mouse mutant (Ift88): R2b macrophages express CD206/Mrc1 and Ym1, classical 
‘M2’ markers and appeared to stimulate cystogenesis in this model 47. The role of PGE2 and 
particularly EP4 in regulating the accumulation and/or activation of M2 and R2b macrophages 
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in cystic kidneys merits further investigation. It would be interesting to test the ability of EP4 
(or EP2) agonists to induce anti-inflammatory effects in this and other PKD models as has been 
reported elsewhere 37, 38. However we predict that this is likely to induce direct proliferative 
effects on cystic epithelial cells. 
Our study has some limitations. We only tested the effects of blocking EP2 and EP4 in 
the earliest phase of disease (PN1-21) coinciding with the peak of cyst formation. Our results 
therefore do not exclude a role for EP2 or EP4 in the subsequent stages of disease e.g. in the 
late development of fibrosis in this model. Second, the Pkd1nl/nl model is an early-onset model 
with significant cystic disease detectable at birth. We did not test the role of blocking EP2 or 
EP4 in utero as this could have interfered with embryonic development. A genetic approach 
would be necessary to test an earlier role for EP2 or EP4 deficiency in the cystic phenotype.  
In conclusion, we have shown that that PGE2 induces cyst formation and expansion via 
activation of EP2 and EP4 receptors through stimulating cell proliferation and decreasing cell 
apoptosis. Despite the positive effects of EP2 and EP4 antagonists on slowing down cyst 
growth in vitro, the more complex effects of inhibiting EP2 or EP4 in vivo resulted in a more 




Madin-Darby Canine Kidney II (MDCK II) cells were cultured in DMEM (GIBCO) 
supplemented with 10 % fetal calf serum (Sigma-Aldrich), 50 U/ml Penicillin/Streptomycin 
(Lonza), 2 mmol/l L-glutamine (Lonza) and maintained at 37 °C in a humidified atmosphere 
of 5 % CO2. The generation of conditionally immortalized human normal (UCL93) and PKD1 
cyst-lining epithelial cells (OX161) has been previously described 24, 48. In 3D culture, OX161 
cells gave rise to predominant cystic (60%) but also simple tubular structures or complex 
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tubulocystic structures. We recloned this line by single cell dilution to identify clones with a 
higher ratio (90%) of cysts in 3D culture and chose clone 1 (C1) for further study. Immortalized 
human cells were cultured in DMEM (GIBCO) supplemented with 5 % Nu-Serum (Corning), 
50 U/ml Penicillin/Streptomycin (Lonza), 2 mmol/l L-glutamine (Lonza) and maintained at 33 
°C in a humidified atmosphere of 5 % CO2. 
 
Experimental animals and study design 
All animal experiments were performed under the authority of a UK Home Office license. 
Hypomorphic Pkd1nl/nl harboring an intronic neomycin-cassette in Pkd1 gene and their 
Pkd1wt/wt and Pkd1wt/nl littermates were sacrificed at different ages from PN1 to PN70 to study 
the evolution of the disease (n=2-11  per group) 25. Pax8rtTA-TetO-Cre-Pkd1f/f mice (Pkd1fl/fl) 
were induced using doxycycline (DOX) by daily IP injections for three days (5mg/kg/day, 
PN13–15) 26. To study the effect of EP2 and EP4 antagonists on disease progression, Pkd1nl/nl 
(n=6-7) and Pkd1fl/fl (n=8-12) were divided into 4 groups: one vehicle-treated control group, 
one group treated with 5mg/kg/day PF-04418948, a selective EP2 antagonist, one group treated 
with 10mg/kg/day ONO-AE3-208, a selective EP4 antagonist and one group treated with 
5mg/kg/day PF-04418948 and 10mg/kg/day ONOAE3-208 in combination. Pkd1nl/nl mice:  
from PN1 to PN7, drugs were dissolved in the drinking water and delivered to the pups through 
the milk and from PN7 to PN20, drugs were administered by daily intraperitoneal injections. 
Mice from the vehicle group mice received daily intraperitoneal injections of DMSO in 
Kolliphor® EL (Sigma-Aldrich). Mice were sacrificed at PN21, corresponding to the peak of 
the disease. Pkd1fl/fl mice: from PN16 to PN29, drugs were administered by daily 
intraperitoneal injections. Mice from the vehicle group mice received daily intraperitoneal 
injections of DMSO in Kolliphor® EL (Sigma-Aldrich). Mice were sacrificed at PN30, 




Cyclic AMP Enzyme‐Linked Immunosorbent Assays 
Kidneys were mechanically homogenized in 0.1 M HCl (Acros Organics) using pre-filled 
Triple-pure zirconium beads (Benchmark Scientific) and a microtube homogenizer 
(Benchmark Scientific) at 4 °C. After centrifugation at 10000 x g for 10 minutes, cAMP from 
the supernatant were quantified using an enzyme immunoassay kit (Enzo) following the 
manufacturer’s instructions without acetylation.  
Cyclic AMP extracted from cells was quantified using an in-house ELISA we have developed 
and validated against the commercial ELISA (Supplemental Figure S8E). After 24 hours of 
starvation, confluent cells were incubated for 30 min with 0.25 mmol/l 3-isobutyl-1-
methylxanthine (Sigma-Aldrich) and 5 mg/ml lactalbumin hydrolysate (Sigma-Aldrich) prior 
to incubation with drugs to be tested (Sigma-Aldrich) for 1 hour. Cells were lysed in 0.1 mol/l 
HCl and cAMP was measured as followed. ELISA 96 well-EIA/RIA Plates plates (Costar) 
were coated overnight with 5 µg/ml Goat Anti-Rabbit IgG Antibody (Millipore) in PBS. After 
washing the plate with 0.05 % Tween® 20 in PBS, pH 7.2-7.4, the plates were blocked with 1 
% BSA (Acros-Organics) in PBS pH 7.2-7.4 for 1 hour at RT followed by additional washes 
with washing buffer. Competitive reactions to measure cAMP were done by pipetting into 
wells the same volume of cAMP lysate, neutralizing reagent (Tris-Base 0.1 mol/l, Sigma-
Aldrich), rabbit anti-cAMP Antibody (Genscript), cAMP-HRP (Genscript) and incubating the 
plate for 2 hours at RT on a plate shaker. Known concentrations of cAMP (Sigma-Aldrich) 
diluted in 0.1 mol/l HCl were used to generate a standard curve covering the concentration 
range 3 to 729 pmol/ml. After extensive washes, the plate was incubated with TMB substrate 
(ThermoFischer) at room temperature for ~20 min after which stop solution (2 M sulfuric acid) 
was added and the absorbance was measured at 450 nm using ELISA plate reader. Protein 
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concentration was quantified using a DC protein assay kit (Bio-rad) and used to normalise 
cAMP concentrations. 
 
See the Online Supplement for description of other methods used in this study. 
 
Statistical analysis 
Data are presented as means values ± SEM. Statistical analysis were performed with GraphPad 
Prism software. The degree of significance is denoted as following: *P <0.05; **P <0.01; 
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Supplementary Figure S1: PGE2 stimulates cell proliferation, decreases cell apoptosis and 
induces cAMP formation in MDCK II and OX161-C1 cells. 
Supplementary Figure S2: EP2 and EP4 activation increase cell proliferation and inhibit cell 
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Supplementary Figure S6: EP1, EP2, EP3 and EP4 gene expression in Pkd1wt,wt, Pkd1wt,nl  
and Pkd1nl,nl kidneys from post-natal weeks 2 to 10. 
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Figure 1: PGE2 inhibits tubulogenesis and promotes cystogenesis through EP2 and EP4 
receptors. 
PGE2 (A, B), ONO-AE1-259-01, an EP2 receptor agonist, or ONO-AE1-329, an EP4 receptor 
agonist (C, D) inhibit spontaneous tubulogenesis in UCL93, a non-cystic human renal epithelial 
cell line, grown initially for 6 d to promote tubular formation and then incubated for a further 
14 days with compounds. Scale bar, 500 µm. Values are expressed as means ±SEM, n>100 
structures per condition. PGE2 (E), ONO-AE1-259-01,or ONO-AE1-329 (F) stimulate cAMP 
accumulation in UCL93 cells after 60 min incubation Values are expressed as means ±SEM, 
n=6. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001 compared with the control group. 
Statistical significances were determined using a one-way ANOVA followed by Dunnett’s 
multiple comparison test or an Unpaired t-test. 
 
Figure 2: PGE2 induces cyst growth by increasing proliferation and decreasing apoptosis. 
PGE2 stimulates cyst growth in MDCK II and OX161-C1 cells in a dose and time-dependent 
manner (A-C). Scale bar, 50 µm. Values are expressed as means ±SEM, n=30–78 cysts per 
condition for MDCK II and n=84–113 cysts per condition for OX161-C1. *P<0.05; **P<0.01; 
***P<0.001; ****P<0.0001 compared with the control group. Statistical significance was 
determined using a two-way ANOVA followed by Tukey’s multiple comparison test. PGE2 
stimulates cell proliferation (D, E) and inhibits apoptosis (F, G) in a dose dependent manner in 
MDCK II cysts. The proliferative rate at day 10 was quantified as the percentage of Ki-67 
positive cells per cyst. The apoptotic rate was quantified as the percentage of cysts with >5 
cleaved caspase-3 positive nuclei. Values are expressed as means ±SEM, n=30 cyst per 
condition. *P<0.05; **P<0.01; ***P<0.001 compared with the control group. Statistical 
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significances were determined using a one-way ANOVA followed by Dunnett’s multiple 
comparison test. 
 
Figure 3: EP2 and EP4 activation induce cyst growth of MDCK II and OX161-C1 cells 
The EP2 receptor agonist ONO-AE1-259-01 (A) or the EP4 receptor agonist ONO-AE1-329 
(B) stimulated cyst growth in MDCK II and OX161-C1 cells. Values are expressed as means 
±SEM, n=45–72 cysts per condition for MDCK II and n=73–162 cysts per condition for 
OX161-C1. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001 compared with the control 
group. Statistical significance was determined using a two-way ANOVA followed by Tukey’s 
multiple comparison test. (C) Example of MDCKII cysts after 20 d of ONO-AE1-259-01 or 
ONO-AE1-329. Scale bar, 100 µm. (D) Example of OX161-C1 cysts after 10, 14 and 20 d 
incubation with ONO-AE1-259-01 or ONO-AE1-329. Scale bar, 50 µm. ONO-AE1-259-01 or 
ONO-AE1-329 stimulate cyclic AMP accumulation in MDCK II (E) and a OX161-C1 cells 
(F) after 60 min. Values are expressed as means ±SEM, n=6. *P<0.05; **P<0.01 compared 
with the control group. Statistical significances were determined using a one-way ANOVA 
followed by Dunnett’s multiple comparison test or an Unpaired t-test. 
  
Figure 4: EP2 and EP4 antagonists abolish PGE2-induced cyst growth in vitro. 
The effect of PGE2 (10nM) on cyst growth in MDCK II (A, B) and OX161-C1 (C, D) cells is 
blocked by EP2 (ONO-AE8-111) or EP4 (ONO-AE3-208) selective antagonists after 14 d and 
10 d respectively Values are expressed as means ±SEM, n=64–75 cysts per condition for 
MDCK II and n=101–144 cysts per condition for OX161-C1. *P<0.05; **P<0.01; 
***P<0.001; ****P<0.0001 compared with the PGE2 group (▪). Statistical significance was 
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determined using the non-parametric Kruskal-Wallis test followed by a Dunn’s multiple 
comparisons test. 
 
Figure 5: The evolution of cystic disease in Pkd1nl/nl mice is associated with an up-
regulation of PGE2 synthesis. 
Two Kidney-to-body weight ratio (A), cystic index (B), renal cAMP content (C) and Ptgs2 
mRNA (D) were measured in Pkd1wt,wt and Pkd1nl,nl kidneys from PN14 to PN70. Values are 
expressed as means ±SEM (n=4–11 per group). **P<0.01; ***P<0.001; ****P<0.0001 
compared to Pkd1wt,wt at the same age. Statistical significance was determined using a two-way 
ANOVA followed by Tukey’s multiple comparison test. (E) PGE2 concentrations were 
measured on whole kidney lysates from 4-week-old Pkd1wt,wt and Pkd1nl,nl. Values are 
expressed as means ±SEM (n=6 per group). **P<0.01 compared to Pkd1wt,wt . Statistical 
significance was determined using an Unpaired t-test. 
 
Figure 6: Administration of EP2 and EP4 antagonists worsened the cystic phenotype of 
Pkd1nl,nl mice. 
(A) Outline of the experimental design of the in vivo experiments. (B) Kidney weight of PN21 
Pkd1nl,nl  mice treated with EP2 or EP4 antagonists. (C) Gross morphology of Pkd1nl,nl kidneys 
from mice treated with EP2 or EP4 antagonists. Two kidney-to-body weight ratio (2KW/BW, 
D), cystic index (E) and (F) representative images of PAS-stained kidney sections from 
Pkd1nl,nl kidneys from mice treated with EP2 or EP4 antagonists. (G) Percentage of Ki-67-
positive cells or (H) F4/80 positive cells in kidney sections from mice treated with EP2 or EP4 
antagonists. (I) Correlation between the percentage of F4/80-positive cells and fractional 
kidney weights. Values are expressed as means ±SEM (n=6–7 per group). *P<0.05; **P<0.01; 
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***P<0.001 compared to vehicle group. Statistical significance was determined using an 
unpaired t-test. 
 
Figure 7: Administration of an EP4 antagonist increased the cystic phenotype of 
Pkd1fl,fl mice. 
(A) Outline of experimental strategy. Kidney weight (g, B) and Kidney-to-body weight ratio 
(2KW/BW, C) of 30-day-old Pkd1fl,fl mice treated with EP2 or EP4 antagonists. (D) Gross 
morphology of Pkd1fl,fl kidneys from mice treated with EP2 or EP4 antagonists. Cystic index 
(%, E) and Kidney cysts (Number of cysts, F) of Pkd1fl,fl kidneys from mice treated with EP2 
or EP4 antagonists. (G) Representative images of H&E stained kidney sections from Pkd1fl,fl 
kidneys from mice treated with EP2 or EP4 antagonists. (H) Percentage of Ki-67-positive cells 
on kidneys sections from mice treated with EP2 or EP4 antagonists. (I) Percentage of F4/80-
positive cells on kidneys sections from mice treated with EP2 or EP4 antagonists. (J) 
Correlation between the percentage of F4/80-positive cells and kidney-to-body weight ratio. 
Values are expressed as means ±SEM, n=8–12 mice per group. *P<0.05; **P<0.01; 
***P<0.001 compared to vehicle group. Statistical significance was determined using an 
unpaired t-test. 
 
Figure 8: Macrophage subtypes in EP4 antagonist treated mice. 
(A) Fraction of Nos2-F4/80 and (B) Ym1-F4/80 macrophaes from Pkd1nl,nl (left) or Pkd1fl,fl 
mice (right) in vehicle and EP4 antagonist groups. Values are expressed as means ±SEM, n=4 
mice per group with five randomly selected regions used for counting. *P<0.05; **P<0.01; 
***P<0.001 compared to vehicle group. Statistical significance was determined using an 
unpaired t-test. (C) Fluorescent  labelling of kidney sections from Pkd1nl,nl mice stained with 
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Mrc1 (Red) and DAPI (Grey). The boxed area is expanded in the right image to show the 
presence of multiple Mrc1 positive macrophages surrounding a medium sized cyst. (D) Mrc1 
positive cells were quantified in Pkd1fl,fl mice treated with vehicle and EP4 antagonist. (F) 
Correlation between the percentage of F4/80-positive cells and MRC1-positive cells present 
in serial sections from the same animals. Values are expressed as means ±SEM, n=11-12 
mice per group. *P<0.05; **P<0.01 compared to vehicle group. Statistical significance was 
determined using Welch's t-test.  
 
Figure 9: The likely roles of EP2 and EP4 in ADPKD pathogenesis. 
(A) In vitro, PGE2 enhances cyst growth in vitro by stimulating epithelial cell (EC) 
proliferation, decreasing epithelial cell apoptosis and stimulating chloride (Cl-) secretion 
through EP2 and EP4 mediated cAMP production. (B) In vivo, EP2 and EP4 antagonists also 
induce an increase in macrophage number which itself leads to an increase in EC injury and 
proliferation, counteracting the direct effects of EP2 and EP4 on cyst epithelia. The graphical 
illustration was drawn by using the images from Servier Medical Art by Les Laboratoires 






































































P G E 2  (n M )








* * * *
O N O -A E 1 -2 5 9 -0 1
(µ M )
O N O -A E 1 -3 2 9
(µ M )
* * * *
























cAMP concentrations cAMP concentrations














































P G E 2  (n M )
*
**






























P G E 2  (n M )
Figure 2
1 0 1 4 2 0
0
2 0 0 0
4 0 0 0
6 0 0 0
8 0 0 0

























P G E 2  (n M )
* *
* *
* * * *
* * * *
* *
8 1 0 1 4
0
5 0 0 0 0
1 0 0 0 0 0

























P G E 2  (n M )
*
* * *

















































































































































1 0 1 4 2 0
0
2 0 0 0
4 0 0 0
6 0 0 0







* * * *
* * * *
* * * *
* * * *
* * * *
* * * *
* * * *
O N O -A E 1 -3 2 9
(µ M )
1 0 1 4 2 0
0
2 0 0 0
4 0 0 0
6 0 0 0






O N O -A E 1 -2 5 9 -0 1
(µ M )
* * * *
* * * *
* * * *
* * * * * * * *
* * * *
*
* * * *
Figure 3
1 0 1 4 2 0
0
5 0 0 0 0
1 0 0 0 0 0






















* * * *
* * * *
* * * *
* * * *
* * * ** * * *
A
MDCK II OX161-C1
1 0 1 4 2 0
0
5 0 0 0 0
1 0 0 0 0 0
























* * * *

























































0 0 0 .0 1 0 .1 1 1 0
0
2 0 0 0
4 0 0 0














E P 4  a n ta g o n is t
O N O -A E 3 -2 0 8  (µ M )




0 0 0 .0 1 0 .1 1 1 0
0
5 0 0 0 0
1 0 0 0 0 0














E P 4  a n ta g o n is t
O N O -A E 3 -2 0 8  (µ M )
P G E 2  1 0 n M
* * * *
* * * *
* * * *
* * * *
0 0 0 .0 1 0 .1 1 1 0
0
4 0 0 0 0
8 0 0 0 0














E P 2  a n ta g o n is t
O N O -A E 8 -1 1 1  (µ M )
P G E 2  1 0 n M
* * *
* * * * * *
* * * *
0 0 0 .0 1 0 .1 1 1 0
0
2 0 0 0
4 0 0 0
6 0 0 0














E P 2  a n ta g o n is t
O N O -A E 8 -1 1 1  (µ M )













P k d 1
w t,w t




1 0 0 0















































































n l,n l* * * *
* * * *











* * * *
* * * *
* * * *
* * * * * * * *
* * * *












* * * *




Both Kidney Weight / Body Weight Cystic index Renal cAMP level
Ptgs2 PGE2
Cyst Number=292
Av. cyst Area=34049 µm2 
CI=46.59 %
Vehicle EP2 antagonist EP4 antagonist EP2+4
Cyst Number=341
Av. cyst Area=39642 µm2 
CI=57.89 %
Cyst Number=424
Av. cyst Area=38576 µm2 
CI=60.1 %
Cyst Number=375



















































R = 0 .4 1 1 2


















































































































































































D-0 D-1 D-7 D-21
- Neutralized NaOH (Vehicle)
- 5mg/kg/day PF-04418948
- 10mg/kg/day ONO-AE3-208









Proliferation Inflammation Treated Pkd1nl,nl


































































































































































































































































































C DAPI MRC1 DAPI MRC1
300µm 50µm





F4/80 Positive cells %
M
R
C
1
 P
o
s
it
iv
e
 c
e
ll
s
 %
R=0.6036
P=0.002290
E
Vehicle EP4
0.0
0.1
0.2
0.3
0.4
0.5
Y
M
1
-F
4
/8
0
 P
o
s
it
iv
e
 c
e
ll
s
 /
F
4
/8
0
 P
o
s
it
iv
e
 c
e
ll
s
***
Pkd1fl,fl
Vehicle EP4
0.0
0.1
0.2
0.3
0.4
Y
M
1
-F
4
/8
0
 P
o
s
it
iv
e
 c
e
ll
s
 /
F
4
/8
0
 P
o
s
it
iv
e
 c
e
ll
s
*
Pkd1nl,nl
Figure 8
A
B
200µm200µm
Vehicle EP4
0.0
0.2
0.4
0.6
0.8
1.0
N
O
S
2
-F
4
/8
0
 P
o
s
it
iv
e
 c
e
ll
s
 /
F
4
/8
0
 P
o
s
it
iv
e
 c
e
ll
s
Vehicle EP4
0.0
0.2
0.4
0.6
0.8
1.0
N
O
S
2
-F
4
/8
0
 P
o
s
it
iv
e
 c
e
ll
s
 /
F
4
/8
0
 P
o
s
it
iv
e
 c
e
ll
s
Pkd1nl,nl
Pkd1fl,fl
